Wiseman C, Hood Y, Presant C, Kennedy P
Wilshire Oncology Medical Group, St. Vincent Medical Center, Los Angeles CA 90057.
Mol Biother. 1991 Jun;3(2):63-7.
We have initiated a clinical trial in 7 patients using low-dose OKT-3 monoclonal antibody, 50 mcg, followed 24 hours later by low-dose cyclophosphamide, 300 mg/m2. Complete data in 5 patients indicate a significant up-regulation of the number of peripheral blood lymphocytes. Before treatment, the mean (+/- standard deviation) total lymphocyte count was 524 (+/- 364)/mm3. After 4 weeks the value rose 64% to 860 (+/- 243)/mm3, (P less than .025, Student's t test). Similar changes were observed for the CD3+, CD4+, CD8+, and CD16+ (NK) lymphocyte subsets. The mean CD3+ population rose from 372 (+/- 325)/mm3 to 593 (+/- 300)/mm3 (P less than .025), the mean CD4+ group rose from 209 (+/- 142)/mm3 to 321 (+/- 104)/mm3 (P less than .05), the CD8+ cells rose from 218 (+/- 205)/mm3 to 341 (+/- 197)/mm3 (P less than .05), and the CD16+ (NK cells) rose from 80 (+/- 37)/mm3 to 157 (+/- 63)/mm3 (P less than .025). Statistically significant up-regulation occurred for all patients. The fraction of each lymphocyte subset and the T4/T8 ratio did not change. OKT-3/cyclophosphamide appears to modulate the number of circulating lymphocytes in human cancer patients.
